Skip to main content
Fig. 1 | AIDS Research and Therapy

Fig. 1

From: Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine

Fig. 1

Changes in CD4/CD8 ratio after switching to cabotegravir plus rilpivirine. Changes in CD4/CD8 ratio (A), CD4 counts (B), and CD8 counts (C) before and after the switch to cabotegravir plus rilpivirine in all participants are shown. The analysis for each antiretroviral therapy regimen prior to switching shows changes in CD4/CD8 ratio (D), CD4 counts (E), and CD8 counts (F) in the TAF-based regimen group, and changes in CD4/CD8 ratio (G), CD4 counts (H), and CD8 counts (I) in the DTG-based regimen group. Baseline, at the start of oral-lead-in; month 0, at the start of injectable cabotegravir plus rilpivirine. The p-values in the graphs are calculated by the Wilcoxon signed-rank test comparing the values at baseline and at month 3. TAF, tenofovir alafenamide; DTG, dolutegravir

Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us